Clinical trial
A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM).
NCT05214001 is registered in ClinicalTrials.gov with Messoud Ashina, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM).
- Lead sponsor
- Messoud Ashina, MD
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- June 30, 2022
- Completion date
- April 15, 2024
- Enrollment
- 8 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.